Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.

2.50
Hdl Handle:
http://hdl.handle.net/10541/74916
Title:
Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Authors:
Barnes, Nicola L P; Khavari, Sahar; Boland, Gary P; Cramer, Angela; Knox, W Fiona; Bundred, Nigel J
Abstract:
The type 1 tyrosine kinase receptor HER2 (c-erbB2/neu) is associated with resistance to hormone therapy and poor survival in invasive breast cancer, whereas HER4 expression is associated with endocrine responsiveness. Patterns of tyrosine kinase receptor coexpression may aid prediction of recurrence risk after surgery for ductal carcinoma in situ (DCIS). Women who had undergone surgery for pure DCIS were studied. Out of 129 primary tumors, 39 had recurred and 90 had not recurred after 5 years of follow-up. Primary tumors were compared for HER2, HER3, and HER4, estrogen receptor, and Ki67 by immunohistochemistry. HER2 was expressed in 58%, HER3 in 49%, and HER4 in 63% of nonrecurrent DCIS, compared with HER2 expression in 82% (P = 0.008), HER3 expression in 71% (P = 0.04), and HER4 expression in 36% (P = 0.004) in DCIS that subsequently recurred. Dually expressing HER2/4 DCIS was more likely to be estrogen receptor positive than HER2-only-expressing DCIS (73% versus 53%; P = 0.05). HER2 expression was associated with a higher percentage and HER4 expression a significantly lower percentage of proliferating DCIS cells (median, 13.8% versus 8.4%; P = 0.001). Coexpression of HER2 with HER4 was associated with reduced recurrence compared with HER2-only positive DCIS (P = 0.003). This association remained significant when analyzing only high nuclear-grade DCIS (P = 0.015). Low nuclear grade, low proliferation rate and presence of HER4 expression were independent predictors of nonrecurrence. Potentially, HER4 expression may identify women who could avoid radiotherapy after breast-conserving surgery for DCIS.
Affiliation:
Department of Academic Surgery, South Manchester University Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, United Kingdom.
Citation:
Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. 2005, 11 (6):2163-8 Clin. Cancer Res.
Journal:
Clinical Cancer Research
Issue Date:
15-Mar-2005
URI:
http://hdl.handle.net/10541/74916
DOI:
10.1158/1078-0432.CCR-04-1633
PubMed ID:
15788662
Type:
Article
Language:
en
ISSN:
1078-0432
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorBarnes, Nicola L P-
dc.contributor.authorKhavari, Sahar-
dc.contributor.authorBoland, Gary P-
dc.contributor.authorCramer, Angela-
dc.contributor.authorKnox, W Fiona-
dc.contributor.authorBundred, Nigel J-
dc.date.accessioned2009-07-22T10:05:23Z-
dc.date.available2009-07-22T10:05:23Z-
dc.date.issued2005-03-15-
dc.identifier.citationAbsence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. 2005, 11 (6):2163-8 Clin. Cancer Res.en
dc.identifier.issn1078-0432-
dc.identifier.pmid15788662-
dc.identifier.doi10.1158/1078-0432.CCR-04-1633-
dc.identifier.urihttp://hdl.handle.net/10541/74916-
dc.description.abstractThe type 1 tyrosine kinase receptor HER2 (c-erbB2/neu) is associated with resistance to hormone therapy and poor survival in invasive breast cancer, whereas HER4 expression is associated with endocrine responsiveness. Patterns of tyrosine kinase receptor coexpression may aid prediction of recurrence risk after surgery for ductal carcinoma in situ (DCIS). Women who had undergone surgery for pure DCIS were studied. Out of 129 primary tumors, 39 had recurred and 90 had not recurred after 5 years of follow-up. Primary tumors were compared for HER2, HER3, and HER4, estrogen receptor, and Ki67 by immunohistochemistry. HER2 was expressed in 58%, HER3 in 49%, and HER4 in 63% of nonrecurrent DCIS, compared with HER2 expression in 82% (P = 0.008), HER3 expression in 71% (P = 0.04), and HER4 expression in 36% (P = 0.004) in DCIS that subsequently recurred. Dually expressing HER2/4 DCIS was more likely to be estrogen receptor positive than HER2-only-expressing DCIS (73% versus 53%; P = 0.05). HER2 expression was associated with a higher percentage and HER4 expression a significantly lower percentage of proliferating DCIS cells (median, 13.8% versus 8.4%; P = 0.001). Coexpression of HER2 with HER4 was associated with reduced recurrence compared with HER2-only positive DCIS (P = 0.003). This association remained significant when analyzing only high nuclear-grade DCIS (P = 0.015). Low nuclear grade, low proliferation rate and presence of HER4 expression were independent predictors of nonrecurrence. Potentially, HER4 expression may identify women who could avoid radiotherapy after breast-conserving surgery for DCIS.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Invasivenessen
dc.subjectCancer Recurrenceen
dc.subjectTumour Markersen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCarcinoma, Intraductal, Noninfiltrating-
dc.subject.meshCell Proliferation-
dc.subject.meshFemale-
dc.subject.meshGene Expression Regulation, Neoplastic-
dc.subject.meshHumans-
dc.subject.meshImmunoenzyme Techniques-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Invasiveness-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshPredictive Value of Tests-
dc.subject.meshReceptor, Epidermal Growth Factor-
dc.subject.meshReceptor, erbB-2-
dc.subject.meshReceptor, erbB-3-
dc.subject.meshReceptors, Estrogen-
dc.subject.meshTumor Markers, Biological-
dc.titleAbsence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.en
dc.typeArticleen
dc.contributor.departmentDepartment of Academic Surgery, South Manchester University Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, United Kingdom.en
dc.identifier.journalClinical Cancer Researchen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.